Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma.
The analysis highlights History, Names and Overview as prominent areas in the source structure around Relatlimab.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
The extracted context around Relatlimab shows recurring relationship patterns in the source. For example, Relatlimab → INN, United States Adopted Name, USAN Another extracted example is Relatlimab → CA: ℞-only, US: ℞-only only in combination with nivolumab. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
lag-3 nivolumab combination melanoma treatment pardoll new immune checkpoint cancer antibody lymphocyte activation gene-3 names drew 2022 inhibitor cells proteins
TTTA extracted 21 structured relationships around Relatlimab. Examples in this analysis include Relatlimab → ATC code → None and Relatlimab → CAS Number → 1673516-98-7. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Relatlimab | ATC code | None | 1.00 | infobox |
| Relatlimab | CAS Number | 1673516-98-7 | 1.00 | infobox |
| Relatlimab | Drug class | Antineoplastic | 1.00 | infobox |
| Relatlimab | DrugBank | DB14851 | 1.00 | infobox |
| Relatlimab | Formula | C6472H9922N1710O2024S38 | 1.00 | infobox |
| Relatlimab | KEGG | D11350 | 1.00 | infobox |
| Relatlimab | Legal status | CA: ℞-only | 1.00 | infobox |
| Relatlimab | Legal status | US: ℞-only only in combination with nivolumab | 1.00 | infobox |
| Relatlimab | License data | US DailyMed: Relatlimab | 1.00 | infobox |
| Relatlimab | Molar mass | 145288.79 g·mol−1 | 1.00 | infobox |
| Relatlimab | Other names | BMS-986016, relatlimab-rmbw | 1.00 | infobox |
| Relatlimab | Routes of administration | Intravenous | 1.00 | infobox |
| Relatlimab | Source | Human | 1.00 | infobox |
| Relatlimab | Target | Lymphocyte activation gene-3 (LAG-3) | 1.00 | infobox |
| Relatlimab | Type | Whole antibody | 1.00 | infobox |
| Relatlimab | UNII | AF75XOF6W3 | 1.00 | infobox |
| Relatlimab | is a | monoclonal antibody designed for the treatment of melanoma | 0.90 | text |
| Relatlimab | is a | Lymphocyte activation gene-3 | 0.90 | text |
The concept neighborhoods around Relatlimab bring nearby vocabulary together. In this analysis, examples include Nivolumab, Combination and New. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Relatlimab, one of the stronger structural bridges in this analysis connects Relatlimab with Overview. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Relatlimab to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as History, Names & Overview, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Relatlimab · EN edition · Analysis: TopicsToTalkAbout